Welcome to our dedicated page for Omeros SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omeros Corporation (NASDAQ: OMER) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, together with AI-generated summaries to help interpret key points. Omeros is a biopharmaceutical company developing and commercializing first-in-class therapeutics for complement-mediated diseases, cancers, and addictive or compulsive disorders, and its filings offer detailed insight into these activities.
Through current reports on Form 8-K, Omeros documents material events such as the U.S. FDA approval of YARTEMLEA (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), conference call announcements, quarterly financial results, and shareholder meeting outcomes. Other 8-K filings describe the asset purchase and license agreement with Novo Nordisk for the MASP-3 inhibitor zaltenibart (OMS906), including eligibility for upfront and milestone payments and tiered royalties, as well as registered direct offerings and related purchase and placement agreements.
Investors can use this page to track how Omeros reports on capital structure and liquidity, including secured term loans, convertible senior notes, equity offerings, and royalty arrangements, all as disclosed in its SEC reports. Filings also outline grant funding for programs like OMS527 for cocaine use disorder and provide context for regulatory submissions and approvals of complement inhibitors such as YARTEMLEA and OMS1029.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important elements of lengthy filings, helping readers quickly locate information on topics such as major transactions, clinical and regulatory milestones, and shareholder votes. Real-time updates from EDGAR ensure that new OMER 8-Ks, 10-Qs, 10-Ks, and Form 4 insider transaction reports become available on this page as they are filed, while the AI layer explains complex language and structures in more accessible terms.
Omeros (OMER) has entered into a registered direct offering of 5,365,853 common shares at $4.10, a 14% premium to the 24-Jul-25 close ($3.59). Gross proceeds total $22.0 million; after the 6% placement fee to D. Boral Capital ($1.32 million) and other expenses, net cash is expected at roughly $20.3 million.
The raise increases shares outstanding from 61.8 million to 67.1 million (≈8.7% dilution) and lifts available cash from ≈$26 million (18-Jul-25) to >$45 million, funding general corporate uses, clinical and pre-clinical pipeline work and working capital. Management retains broad spending discretion.
Key pipeline points: FDA’s BLA for lead MASP-2 antibody narsoplimab in TA-TMA now carries a 26-Dec-25 PDUFA date; EMA review is ongoing with an opinion expected mid-2026. The company is also advancing MASP-3 inhibitor zaltenibart (PNH, C3G) and PDE7 program OMS527 (cocaine use disorder). Omeros is negotiating a potential multi-billion-dollar asset deal that could retire its $67.1 million term loan and part of its 2026 notes.
Despite the premium pricing, the offer adds to a $(193 million) adjusted tangible book deficit and follows an auditor going-concern warning. Investors face immediate dilution of $7.15 per share (net tangible book value basis) and future overhang from 19.6 million outstanding options and convertible notes.
FAQ
What is the current stock price of Omeros (OMER)?
What is the market cap of Omeros (OMER)?
